Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Common Equity (2020 - 2025)

Mirum Pharmaceuticals has reported Common Equity over the past 6 years, most recently at $314.7 million for Q4 2025.

  • Quarterly results put Common Equity at $314.7 million for Q4 2025, up 39.47% from a year ago — trailing twelve months through Dec 2025 was $314.7 million (up 39.47% YoY), and the annual figure for FY2025 was $314.7 million, up 39.47%.
  • Common Equity for Q4 2025 was $314.7 million at Mirum Pharmaceuticals, up from $292.0 million in the prior quarter.
  • Over the last five years, Common Equity for MIRM hit a ceiling of $314.7 million in Q4 2025 and a floor of $56.4 million in Q3 2021.
  • Median Common Equity over the past 5 years was $197.5 million (2022), compared with a mean of $184.6 million.
  • Biggest five-year swings in Common Equity: crashed 53.1% in 2021 and later skyrocketed 200.19% in 2022.
  • Mirum Pharmaceuticals' Common Equity stood at $120.2 million in 2021, then grew by 18.16% to $142.0 million in 2022, then surged by 75.07% to $248.7 million in 2023, then dropped by 9.26% to $225.6 million in 2024, then surged by 39.47% to $314.7 million in 2025.
  • The last three reported values for Common Equity were $314.7 million (Q4 2025), $292.0 million (Q3 2025), and $255.2 million (Q2 2025) per Business Quant data.